Healthcare Stock Soars on Cancer Treatment Update

The security had been previously trending lower

Deputy Editor
Nov 23, 2021 at 10:50 AM
facebook X logo linkedin


The shares of Aptevo Therapeutics Inc (NASDAQ:APVO) are soaring today, up 35% to trade at $8.75 at last check, after the biotech concern announced that one high-risk cancer patient had a complete remission after being treated with its experimental drug, APVO436, combined with chemotherapy. The preliminary data is from an early-stage extension study in patients with acute myeloid leukemia. 

APVO has been steadily dropping on the charts this month, after the stock was rejected by overhead pressure from the 100-day moving average, just above the $18 level. Fresh off its second-straight week of losses, todays' bull gap has Aptevo stock recovering a small portion of that monthly deficit. Year-to-date, the equity is still down 76.6%. 

The two firms covering APVO carry a "buy" rating. Plus, the 12-month consensus price target of $36 is a whopping 316.7% premium to current levels. 

 

 

 

Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.


Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!

 

 
 
 


 
 

Rainmaker Ads CGI